A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain

GNF-2 is an allosteric inhibitor of Bcr-Abl. It was developed as a new class of anti-cancer drug to treat resistant chronic myelogenous leukemia. Recent studies suggest that c-Abl inhibition would provide a neuroprotective effect in animal models of Parkinson’s disease as well as in clinical trials....

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Gyun Jee, Rahman, Md Habibur, Jha, Mithilesh Kumar, Gupta, Deepak Prasad, Park, Sung Hee, Kim, Jae-Hong, Lee, Sun-Hwa, Lee, In-Kyu, Sim, Taebo, Bae, Yong Chul, Lee, Won-Ha, Suk, Kyoungho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535676/
https://www.ncbi.nlm.nih.gov/pubmed/31164822
http://dx.doi.org/10.3389/fphar.2019.00543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535676/
https://www.ncbi.nlm.nih.gov/pubmed/31164822
http://dx.doi.org/10.3389/fphar.2019.00543

Ejemplares similares